Inhibrx Biosciences, Inc.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
Exhibits
The exhibits listed in the accompanying “Index to Exhibits” below are filed or incorporated by reference as part of this Annual Report.
Financial Statement Schedules
See “Index to Consolidated Financial Statements” at Item 8 to this Annual Report. Other financial statement schedules have not been included because they are not applicable or the information is included in the financial statements or notes thereto.
Index to Exhibits
| Exhibit No. | Description of Exhibit | Filed Herewith | Form | Incorporated By Reference File No. | Date Filed |
|---|---|---|---|---|---|
| 2.1^ | Agreement and Plan of Merger, dated as of January 22, 2024, by and among Inhibrx, Inc., Aventis Inc., and Art Acquisition Sub, Inc. | 8-K | 001-39452 | 1/23/2024 | |
| 2.2^ | Separation and Distribution Agreement, dated as of January 22, 2024, by and among Inhibrx, Inc., Ibex SpinCo, Inc., and Aventis Inc. | 8-K | 001-39452 | 1/23/2024 | |
| 3.1 | Amended & Restated Certificate of Incorporation of Inhibrx Biosciences, Inc. | 8-K | 001-42031 | 5/30/2024 | |
| 3.2 | Amended & Restated Bylaws of Inhibrx Biosciences, Inc. | 8-K | 001-42031 | 5/30/2024 | |
| 4.1 | Form of Warrant to Purchase Stock. | 10 | 001-42031 | 4/25/2024 | |
| 4.2 | Form of Warrant to Purchase Stock by and between Inhibrx Biosciences, Inc. and entities affiliated with Oxford Finance LLC. | 8-K | 001-42031 | 1/13/2025 | |
| 4.3 | Description of Registered Securities | X | |||
| 10.1^ | Transition Services Agreement, dated as of May 29, 2024, by and between Inhibrx Biosciences, Inc. and Inhibrx, Inc. | 8-K | 001-42031 | 5/30/2024 | |
| 10.2+ | Form of Indemnification Agreement. | 10 | 001-42031 | 4/25/2024 | |
| 10.3^ | Registration Rights Agreement, dated as of May 29, 2024, by and among Inhibrx Biosciences, Inc. and the parties thereto. | 8-K | 001-42031 | 5/30/2024 | |
| 10.4+ | Executive Employment Agreement, effective as of May 30, 2024, by and between Inhibrx Biosciences, Inc. and Mark Lappe. | S-1 | 333-280127 | 6/11/2024 | |
| 10.5+ | Executive Employment Agreement, effective as of May 30, 2024, by and between Inhibrx Biosciences, Inc. and Brendan Eckelman, Ph.D. | S-1 | 333-280127 | 6/11/2024 | |
| 10.6+ | Executive Employment Agreement, effective as of May 30, 2024, by and between Inhibrx Biosciences, Inc. and Kelly Deck. | S-1 | 333-280127 | 6/11/2024 | |
| 10.7+ | 2024 Omnibus Incentive Plan. | S-8 | 333-279840 | 5/30/2024 | |
| 10.8+ | Form of Stock Option Grant Notice under the 2024 Omnibus Incentive Plan. | 8-K | 001-42031 | 5/30/2024 | |
| 10.9+ | Form of Restricted Stock Unit Agreement under the 2024 Omnibus Incentive Plan. | S-8 | 333-279840 | 5/30/2024 | |
| 10.10+ | Nonemployee Director Compensation Policy. | 10-Q | 001-42031 | 8/13/2024 | |
| 10.11 | Loan and Security Agreement, dated January 13, 2025, among Inhibrx Biosciences, Inc., Oxford Finance LLC, and the other lenders party thereto. | 8-K | 001-42031 | 1/13/2025 | |
| 19.1 | Inhibrx Biosciences, Inc. Insider Trading Policy | X | |||
| 21.1 | Subsidiaries of the Registrant. | S-1 | 333-280127 | 6/11/2024 | |
| 23.1 | Consent of BDO USA, P.C., independent registered public accounting firm. | X | |||
| 31.1 | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | |||
| 31.2 | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | |||
| 32.1* | Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | |||
| 32.2* | Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | |||
| 97.1 | Inhibrx Biosciences, Inc. Clawback Policy | X | |||
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document | X | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | X | |||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X | |||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X | |||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | X | |||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X | |||
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document contained in Exhibit 101 | X | |||
^ Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally to the SEC a copy of any omitted exhibits or schedules upon request. Pursuant to Item 601(a)(6) of Regulation S-K, certain information from this exhibit have been redacted as their disclosure would constitute a clearly unwarranted invasion of personal privacy.
- Management compensation plan or arrangement.
- This certification is deemed not filed for purposes of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.